Sucampo Pharma (SCMP) Misses Q3 EPS by 1c; Boosts FY14 Earnings Outlook

Sucampo Pharma (NASDAQ: SCMP) reported Q3 EPS of $0.03, $0.01 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $31.5 million versus the consensus estimate of $26.11 million.

Sucampo raised its full year 2014 earnings guidance to $15.0 million to $20.0 million net income, excluding special items, versus previous guidance of $4.0 million to $6.0 million.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• CalPrivate Bank names Andra Frazier as chief credit officer
• Aon names interim CFO as Edmund Reese exits the firm